Cebpbtm1.1Acle/Cebpb+
involves: 129P2/OlaHsd * BALB/c * C57BL/6
|
abnormal skeleton morphology |
J:150006
|
Cebpbtm1.1Acle/Cebpbtm1.1Acle
involves: 129P2/OlaHsd * BALB/c * C57BL/6
|
abnormal bone trabecula morphology |
J:150006
|
|
abnormal osteoblast physiology |
J:150006
|
|
abnormal osteoclast differentiation |
J:150006
|
|
abnormal osteoclast morphology |
J:150006
|
|
abnormal osteoclast physiology |
J:150006
|
|
enhanced osteoblast differentiation |
J:150006
|
|
increased bone mineralization |
J:150006
|
|
increased bone ossification |
J:150006
|
|
increased bone resorption |
J:150006
|
|
increased bone trabecula number |
J:150006
|
|
increased bone volume |
J:150006
|
|
prenatal lethality, incomplete penetrance |
J:150006
|
Cebpbtm1.1Elgaz/Cebpbtm1.1Elgaz
Lyz2em1.1(cre)Elgaz/Lyz2+
BALB/cJ-Cebpbtm1.1Elgaz Lyz2em1.1Elgaz/Elgaz
|
abnormal myeloid cell number |
J:247885
|
|
decreased circulating interleukin-10 level |
J:247885
|
|
decreased susceptibility to bacterial infection |
J:247885
|
|
decreased susceptibility to bacterial infection induced morbidity/mortality |
J:247885
|
|
decreased transforming growth factor beta level |
J:247885
|
|
increased circulating interleukin-6 level |
J:247885
|
|
increased circulating tumor necrosis factor level |
J:247885
|
Cebpbtm1.1Maka/Cebpbtm1.1Maka
Tg(Ins2-cre)23Herr/0
involves: 129P2/OlaHsd * C57BL/6J * CBA/J
|
normal
homeostasis/metabolism phenotype |
J:156725
|
|
increased insulin secretion |
J:156725
|
Cebpbtm1Aki/Cebpbtm1Aki
involves: 129P2/OlaHsd * C57BL/6
|
abnormal macrophage physiology |
J:153025
|
|
abnormal T-helper 1 physiology |
J:153025
|
|
decreased susceptibility to endotoxin shock |
J:153025
|
|
granulomatous inflammation |
J:153025
|
|
increased susceptibility to bacterial infection |
J:153025
|
Cebpbtm1Es/Cebpbtm1Es
Tg(KRT5-cre)5132Jlj/?
involves: 129S1/Sv * C57BL/6J * DBA/2J
|
decreased incidence of tumors by chemical induction |
J:107334
|
|
increased keratinocyte apoptosis |
J:107334
|
Cebpbtm1Es/Cebpbtm1Es
Tg(KRT14-cre/ERT)20Efu/0
involves: 129S1/Sv * C57BL/6 * CD-1
|
abnormal keratinocyte differentiation |
J:158721
|
|
epidermal hyperplasia |
J:158721
|
|
increased keratinocyte proliferation |
J:158721
|
|
normal
integument phenotype |
J:158721
|
|
thick epidermis |
J:158721
|
Cebpbtm1Kish/Cebpb+
involves: 129P2/OlaHsd
|
abnormal skeletal muscle mass |
J:237461
|
Cebpbtm1Kish/Cebpbtm1Kish
involves: 129P2/OlaHsd
|
abnormal brown adipose tissue morphology |
J:45062
|
|
abnormal cell differentiation |
J:45062
|
|
abnormal clavicle morphology |
J:237461
|
|
abnormal macrophage physiology |
J:77003
|
|
abnormal thoracic cage morphology |
J:237461
|
|
abnormal zygomatic arch morphology |
J:237461
|
|
female infertility |
J:45062
|
|
impaired macrophage phagocytosis |
J:77003
|
|
increased interleukin-12 secretion |
J:126085
|
|
increased susceptibility to bacterial infection |
J:77003
|
|
neonatal lethality, incomplete penetrance |
J:45062
|
|
perinatal lethality, incomplete penetrance |
J:77003
|
|
postnatal lethality, incomplete penetrance |
J:45062,
J:77003
|
Cebpbtm1Nerl/Cebpbtm1Nerl
Tg(Ckmm-cre)5Khn/0
involves: 129P2/OlaHsd * C57BL/6 * FVB
|
normal
homeostasis/metabolism phenotype |
J:153686
|
|
normal
muscle phenotype |
J:153686
|
Cebpbtm1Pfj/Cebpb+
B6.Cg-Cebpbtm1Pfj
|
decreased incidence of tumors by chemical induction |
J:73558
|
Cebpbtm1Pfj/Cebpbtm1Pfj
B6.Cg-Cebpbtm1Pfj
|
decreased incidence of induced tumors |
J:73558
|
|
decreased incidence of tumors by chemical induction |
J:73558
|
|
increased keratinocyte apoptosis |
J:73558
|
Cebpbtm1Pfj/Cebpbtm1Pfj
either: 129S1/SvImJ-Cebpbtm1Pfj or (involves: 129S1/SvImJ * C57BL/6)
|
abnormal branching of the mammary ductal tree |
J:48514
|
|
abnormal lactation |
J:48514
|
|
abnormal mammary gland development |
J:48514
|
Cebpbtm1Pfj/Cebpbtm1Pfj
involves: 129S1/Sv * C57BL/6
|
abnormal osteoblast physiology |
J:150006
|
|
abnormal osteoclast differentiation |
J:150006
|
|
abnormal osteoclast morphology |
J:150006
|
|
abnormal osteoclast physiology |
J:150006
|
|
abnormal skeleton morphology |
J:150006
|
|
abnormal tumor necrosis factor level |
J:192313
|
|
absent corpus luteum |
J:43075
|
|
absent estrous cycle |
J:43075
|
|
decreased bone mineralization |
J:150006
|
|
decreased bone ossification |
J:150006
|
|
decreased bone trabecula number |
J:150006
|
|
decreased bone volume |
J:150006
|
|
decreased superovulation rate |
J:43075
|
|
decreased trabecular bone thickness |
J:150006
|
|
female infertility |
J:43075
|
|
impaired granulosa cell differentiation |
J:43075
|
|
impaired luteinization |
J:43075
|
|
impaired ovarian folliculogenesis |
J:43075
|
|
increased bone resorption |
J:150006
|
|
prenatal lethality, incomplete penetrance |
J:43075,
J:150006
|
|
normal
reproductive system phenotype |
J:43075
|
Cebpbtm1Vpo/Cebpb+
involves: 129S/SvEv * C57BL/6 * MF1
|
abnormal mammary gland duct morphology |
J:48513
|
Cebpbtm1Vpo/Cebpbtm1Vpo
FVB.129S-Cebpbtm1Vpo
|
decreased sensitivity to induced cell death |
J:52729
|
Cebpbtm1Vpo/Cebpbtm1Vpo
involves: 129S/SvEv * C57BL/6
|
abnormal brown adipose tissue physiology |
J:117502
|
|
decreased body weight |
J:117502
|
|
decreased brown adipose tissue amount |
J:117502
|
|
decreased epididymal fat pad weight |
J:117502
|
|
decreased lipoprotein lipase activity |
J:117502
|
|
decreased triglyceride level |
J:117502
|
|
impaired adaptive thermogenesis |
J:117502
|
|
increased circulating glucose level |
J:117502
|
|
increased circulating triglyceride level |
J:117502
|
Cebpbtm1Vpo/Cebpbtm1Vpo
involves: 129S/SvEv * C57BL/6 * MF1
|
abnormal branching of the mammary ductal tree |
J:48513
|
|
abnormal gluconeogenesis |
J:49673
|
|
abnormal glucose homeostasis |
J:49673
|
|
abnormal mammary gland development |
J:48513
|
|
abnormal mammary gland duct morphology |
J:48513
|
|
abnormal mammary gland epithelium physiology |
J:48513
|
|
female infertility |
J:48513
|
|
hypoglycemia |
J:49673
|
|
impaired liver regeneration |
J:49673
|
Cebpbtm1Vpo/Cebpbtm1Vpo
involves: 129S/SvEv * MF1
|
abnormal adipose tissue physiology |
J:52286
|
|
abnormal cell-mediated immunity |
J:25215
|
|
abnormal circulating free fatty acids level |
J:52286
|
|
abnormal definitive hematopoiesis |
J:25215
|
|
abnormal enzyme/coenzyme level |
J:52286
|
|
abnormal gluconeogenesis |
J:52286
|
|
abnormal glucose homeostasis |
J:52286,
J:62132
|
|
abnormal humoral immune response |
J:25215
|
|
abnormal innate immunity |
J:25215
|
|
abnormal lipid homeostasis |
J:52286,
J:62132
|
|
abnormal lymph node B cell domain morphology |
J:25215
|
|
abnormal lymph node cortex morphology |
J:25215
|
|
abnormal lymph node medulla morphology |
J:25215
|
|
abnormal lymph node medullary cord morphology |
J:25215
|
|
abnormal lymph node secondary follicle morphology |
J:25215
|
|
abnormal lymph node T cell domain morphology |
J:25215
|
|
abnormal macrophage physiology |
J:25215
|
|
abnormal mucosa-associated lymphoid tissue morphology |
J:25215
|
|
abnormal plasma cell morphology |
J:25215
|
|
abnormal spleen red pulp morphology |
J:25215
|
|
abnormal spleen secondary B follicle morphology |
J:25215
|
|
abnormal spleen white pulp morphology |
J:25215
|
|
abnormal T-helper 1 physiology |
J:25215
|
|
abnormal T-helper 2 physiology |
J:25215
|
|
decreased circulating free fatty acids level |
J:52286,
J:62132
|
|
decreased circulating insulin level |
J:62132
|
|
decreased circulating interleukin-12 level |
J:25215
|
|
decreased circulating leptin level |
J:62132
|
|
decreased circulating triglyceride level |
J:52286
|
|
decreased glycogen catabolism rate |
J:52286
|
|
decreased gonadal fat pad weight |
J:62132
|
|
decreased percent body fat/body weight |
J:62132
|
|
decreased susceptibility to type IV hypersensitivity reaction |
J:25215
|
|
decreased uterine fat pad weight |
J:52286
|
|
enlarged axillary lymph nodes |
J:25215
|
|
enlarged inguinal lymph nodes |
J:25215
|
|
enlarged lymph nodes |
J:25215
|
|
enlarged mesenteric lymph nodes |
J:25215
|
|
enlarged spleen |
J:25215
|
|
enlarged submandibular lymph nodes |
J:25215
|
|
expanded mesangial matrix |
J:25215
|
|
extramedullary hematopoiesis |
J:25215
|
|
glomerulonephritis |
J:25215
|
|
hemosiderosis |
J:25215
|
|
hypoglycemia |
J:52286,
J:62132
|
|
impaired lipolysis |
J:62132
|
|
increased bone marrow cell number |
J:25215
|
|
increased circulating corticosterone level |
J:52286
|
|
increased circulating interleukin-6 level |
J:25215
|
|
increased IgG level |
J:25215
|
|
increased insulin sensitivity |
J:62132
|
|
increased mesangial cell number |
J:25215
|
|
increased muscle cell glucose uptake |
J:62132
|
|
increased susceptibility to fungal infection |
J:25215
|
|
postnatal lethality, incomplete penetrance |
J:25215
|
|
premature death |
J:25215
|
|
renal glomerulus hypertrophy |
J:25215
|
|
skin lesions |
J:25215
|
Cebpbtm2.1Acle/Cebpbtm2.1Acle
involves: 129P2/OlaHsd * BALB/cJ * C57BL/6
|
abnormal osteoclast morphology |
J:155795
|
|
decreased cell proliferation |
J:155795
|
|
decreased osteoclast cell number |
J:155795
|
|
impaired liver regeneration |
J:155795
|
|
increased bone volume |
J:155795
|
|
increased circulating interleukin-6 level |
J:155795
|
|
increased trabecular bone thickness |
J:155795
|
|
normal
reproductive system phenotype |
J:155795
|
Cebpbtm3.1Acle/Cebpbtm3.1Acle
involves: 129P2/OlaHsd * BALB/cJ * C57BL/6
|
no abnormal phenotype detected |
J:155795
|
Cebpbtm3Nerl/Cebpbtm3Nerl
either: B6.129P2-Cebpbtm3Nerl or (involves: 129P2/OlaHsd * C57BL/6)
|
calcified muscle |
J:153686
|
|
decreased skeletal muscle fiber size |
J:153686
|
|
impaired skeletal muscle regeneration |
J:153686
|
|
increased physiological sensitivity to xenobiotic |
J:153686
|
|
myositis |
J:153686
|
|
normal
reproductive system phenotype |
J:153686
|
|
skeletal muscle fibrosis |
J:153686
|
Excel File
Analysis Tools